Introduction {#s1}
============

Multiple Sclerosis Associated Retrovirus (MSRV) is a member of type-W Human Endogenous Retroviruses (HERV-W), an HERV family suggested to be involved in Multiple Sclerosis (MS) pathogenesis [@pone.0053623-Perron1]. The study of the relationship between HERVs and MS began in 1989, when retroviral particles were discovered in cultures of leptomeningeal cells [@pone.0053623-Perron2] and monocytes [@pone.0053623-Perron3] from MS patients. In independent epidemiological studies, an association between MSRV/HERV-W and MS diagnosis [@pone.0053623-Perron1], [@pone.0053623-Dolei1] and prognosis [@pone.0053623-Sotgiu1], [@pone.0053623-Sotgiu2] has been confirmed.

Other HERV families have been also studied in relation with MS: a *HERV-K18* haplotype is associated with MS susceptibility [@pone.0053623-Tai1] and increased levels of *HERV-H* members RNA and antibodies towards peptides derived from *HERV-H* DNA have been found in MS patients compared to controls [@pone.0053623-Christensen1], [@pone.0053623-Laska1].

We have focused on HERV-W because (i) MSRV causes a T cell-mediated neuropathology *in vivo* [@pone.0053623-Firouzi1], (ii) MSRV/HERV-W envelope protein induces a potent activation of innate immunity and subsequent release of pro-inflammatory cytokines, through Toll-like receptor (TLR-4) [@pone.0053623-Rolland1] and (iii) acts as superantigen, producing polyclonal T-lymphocyte activation [@pone.0053623-Perron4]. Moreover, HERV-W env protein can induce oligodendrocyte toxicity inflammation-mediated [@pone.0053623-Antony1]. Along the evolution, most of the HERV proviruses have undergone extensive deletions and mutations and are present in the genome as defective copies unable to replicate. However, HERVs can be transactivated by other viruses also associated with MS pathogenesis as Herpesviruses: Epstein-Barr (EBV) [@pone.0053623-Sutkowski1], Human Herpesvirus-1 (HSV1) [@pone.0053623-Ruprecht1] or Human Herpesvirus-6 (HHV6) [@pone.0053623-Tai2].

Further linking this HERV-W expression with MS, successive studies have evidenced that MSRV env protein was found in the serum of 73% of MS patients and not in controls [@pone.0053623-Perron1] and MSRV*/*HERV-W *pol* and *env* RNAs were significantly elevated in autopsied brain tissue and peripheral blood mononuclear cells (PBMCs) from MS patients versus controls [@pone.0053623-Mameli1], [@pone.0053623-Antony2].

The role of gender in the natural history of MS has different aspects, but the best known fact is the higher prevalence of the disease among women. The sex ratio continues to intrigue researchers and it has been shown that this female predominance has even increased over past decades [@pone.0053623-Orton1], [@pone.0053623-Krokki1]. However, gender issues in MS expand beyond the scope of sex ratio [@pone.0053623-Sadovnick1]. Gender has an impact on various aspects of MS, including age of onset [@pone.0053623-Cossburn1], "parent-of-origin" effect on susceptibility [@pone.0053623-Ramagopalan1], [@pone.0053623-Herrera1] and risk for relatives of MS patients [@pone.0053623-Ebers1].

A potential link between MSRV and the gender differences observed in MS that involves the HERV-W copies on chromosome X has been suggested [@pone.0053623-Perron5]. The exact genomic origin of MSRV is unknown, however, analysis of MSRV-type *env* sequences revealed that some of them could originate from transcripts (in some instances recombined) of defective HERV-W elements [@pone.0053623-Laufer1]; among all the HERV-W locations, the copy on chromosome Xq22.3 has been found to encompass a locus (ERVWE2) encoding a truncated envelope protein, which however cannot explain by itself a full-length protein detection nor detection of virions associated with reverse transcriptase activity [@pone.0053623-Roebke1].

Two components of the HERV-W family have been shown to display immunopathogenic activity that could be relevant for MS: MSRV and *ERVWE1* (from HERV-W7q copy, encoding syncytin-1). *ERVWE1* and MSRV *env* are closely related, but they have a 12-nucleotide difference in the trans-membrane moiety [@pone.0053623-Mameli2], [@pone.0053623-KomurianPradel1]. A discriminatory PCR study has recently shown that only MSRV*-*type *env* and not *ERVWE1* presents an increased expression in PBMCs of multiple sclerosis patients [@pone.0053623-Mameli2]. Besides, the HERV-W7q copy comprising the *ERVWE1* locus has defective *pol* and *gag* genes so it is unlikely to be involved in the genesis of supplementary DNA copies.

In the present study the levels of MSRV-type DNA sequences in PBMCs from MS patients and controls were measured by specific quantitative PCR (qPCR) analysis. The results were analyzed in relation with gender differences and MS clinical scores.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

Informed consent was signed by all the individuals and the study was approved by the Ethics Committee of the Hospital Clinico San Carlos.

Patients and Controls {#s2b}
---------------------

178 MS patients (62.9% women) and 124 controls (ethnically, age and sex matched healthy blood donors; 56.5% women) were included from a single center (Hospital Clinico San Carlos, Madrid). All the patients but 10 were under treatment. All of them were Caucasian, with European ancestors. MS diagnosis was established according to McDonald's criteria [@pone.0053623-McDonald1]. No first or second degree relatives with autoimmune diseases were reported by the control subjects. Clinical and demographic characteristics are enclosed in [Table 1](#pone-0053623-t001){ref-type="table"}. Clinical variables collected included MS course, Expanded Disability Status Scale (EDSS) score [@pone.0053623-Kurtzke1], Multiple Sclerosis Severity Scale (MSSS) score [@pone.0053623-Roxburgh1], years of evolution of the disease and number of relapses within the last two years.
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###### Clinical and demographic characteristics of MS patients and controls, stratified by sex.

![](pone.0053623.t001){#pone-0053623-t001-1}

  Characteristics                                         Patients    Controls     p-value                                                                                                                      
  ----------------------------------------------------- ------------ ----------- ------------ -------------------------------------- ----------- ----------- ----------- -------------------------------------- --------------------------------------
  n (% of total)                                         178 (100)    67 (37.4)   112 (62.6)                    --                    124 (100)   54 (43.5)   70 (56.5)                    --                    n.s[\*](#nt101){ref-type="table-fn"}
  Age (years) (Mean ± SD)                                36.7±10.6    41.4±10.4    39.3±9.5    n.s[\*](#nt101){ref-type="table-fn"}   40.1±9.9    38.8±9.1    41.0±11.6   n.s[\*](#nt101){ref-type="table-fn"}                   n.s
  RR (n (%))                                             112 (64.4)   40 (61.5)   72 (66.1)    n.s[\*](#nt101){ref-type="table-fn"}      --          --          --                        --                                     --
  SP (n (%))                                             38 (21.8)    14 (21.5)   24 (22.0)    n.s[\*](#nt101){ref-type="table-fn"}      --          --          --                        --                                     --
  PP (n (%))                                             24 (13.8)    11 (16.9)   13 (11.9)    n.s[\*](#nt101){ref-type="table-fn"}      --          --          --                        --                                     --
  Disease duration (years)                                8.1±5.6      8.6±6.6     7.7±4.9     n.s[\*](#nt101){ref-type="table-fn"}      --          --          --                        --                                     --
  (Mean ± SD)                                                                                                                                                                                                   
  Number of relapses in the lasttwo years (Mean ± SD)    0.83±1.12    0.63±0.72   0.94±1.29    n.s[\*](#nt101){ref-type="table-fn"}                                                                             
                                                                                                                                                                                                                
  Current EDSS score (Mean ± SD)                          2.93±2.4    2.85±2.24   2.97±2.50    n.s[\*](#nt101){ref-type="table-fn"}      --          --          --                        --                                     --
  Current MSSS score (Mean ± SD)                         3.97±3.09    3.79±2.79   4.08±3.16    n.s[\*](#nt101){ref-type="table-fn"}                                                                             

n.s: Not statistically significant.

Determination of Specificity and Efficiency of the PCR Assay {#s2c}
------------------------------------------------------------

To determine the specificity of the MSRV*-type* set of primers and probe [@pone.0053623-Mameli2], real time PCR assays were performed on serial dilutions of MSRV *env* and s*yncytin-1* plasmids (available at Geneuro S.A, Geneva, Switzerland) confirming that it was able to detect MSRV *env* (GenBank accession number: AF331500) but not s*yncytin-1* (Accession number: AC000064). A standard curve of serial dilutions of human genomic DNA was used to determine the efficiencies of MSRV *env* and *RNAse P* PCR assays (Supporting information: [Figures S1](#pone.0053623.s001){ref-type="supplementary-material"} and [S2](#pone.0053623.s002){ref-type="supplementary-material"}). Efficiency of MSRV *env* assay was determined also by a standard curve of MSRV plasmid (Supporting information: [Figure S3](#pone.0053623.s003){ref-type="supplementary-material"}). Both MSRV standard curves (plasmid and genomic DNA) had similar slopes. The slopes were −3.4 for RNAse P and −3.2 for MSRV.

*In silico* Analysis {#s2d}
--------------------

To determine the number of copies of HERV-W MSRV*-type* potentially detected in the human genome the sequences of the primers and probe [@pone.0053623-Mameli2] were aligned with the BLASTN tool available at Ensembl [@pone.0053623-Ensembl1].

MSRV-*type* DNA Copy Number Quantification {#s2e}
------------------------------------------

PBMCs were obtained from fresh whole blood by centrifugation of CPT tubes (Becton Dickinson, Meylan, France). DNA was extracted from PBMCs with the Qiamp DNA Blood Mini kit (Qiagen, Valencia, CA, USA) following manufacturer's instructions. DNA quality and concentration was assessed by spectrophotometer and sample volumes were adjusted to 10 ng/ul, corresponding to 50 ng of DNA per PCR reaction. Each sample was analyzed in duplicate by real time PCR with a set of primers and probe to detect specifically MSRV*-type env* [@pone.0053623-Mameli2] and RNAse P (Applied Biosystems). *RNAse P* is a single-copy gene and it was used to normalize the results with the DNA load per reaction, avoiding potential errors with pipetting.

Each round included an interplate calibrator (I.P.C), consisting of human DNA with a known copy number of MSRV *env* DNA, and a negative control; they were analyzed for both genes. The assays for the detection of RNAse P and MSRV*-type env* were considered acceptable in each sample when: 1) No amplification was detected in the negative controls; 2) Ct of RNAse P was lower than Mean +2\*S.D of Ct~RNAse\ P~ of all samples; 3) the duplicates of each sample had less than 5% of variability.

Genex® (MultiD analyses AB, Sweden) software was used to normalize sample Cts according to the efficiencies of each assay and also to the Cts of the I.P.C in each round.

The exact number of copies of MSRV*-type* was determined by interpolation of Cts in a standard curve of serial dilutions of MSRV plasmid (available at Geneuro S.A); the exact number of RNAse P copies per reaction was determined by interpolation of Cts in a standard curve of genomic DNA. There is only one copy of RNAse P per haploid genome and the mass of the haploid genome is 3.5 pg [@pone.0053623-Data1], thus interpolating the Cts of RNAse P in the standard curve of genomic DNA the exact quantity of DNA loaded in the reaction is obtained. Results are expressed as MSRV*-type env* copies/pg of DNA.

Statistical Analysis {#s2f}
--------------------

Statistical analyses were performed with SPSS 15.0. Chi-Square test was used to compare qualitative variables. As MSRV load (MSRV*-type env* copies/pg of DNA) was not normally distributed (Kolmogorov-Smirnov test) a log~10~ transformation of the data was made. Data are expressed as mean \[95% confidence interval for the mean\]. ANOVA test was used for comparison of groups.

To compare patients with a high MSRV DNA load with the rest, a cut-off was calculated: Cut-Off = Mean +2\*S.D (log~10~ MSRV*-type env* copies/pg DNA)~Blood\ Donors~; (Cut-Off = 2.22, corresponding to 165 copies/pg of DNA) thus, representing significantly increased values from the normal range in a healthy population. Clinical variables were compared between patients with a MSRV*-type* load above and below the cut-off.

Statistically significant differences were considered when p\<0.05.

Results and Discussion {#s3}
======================

The analyses by qPCR revealed that MSRV-type DNA copy number was more elevated in PBMCs of MS patients (Mean = 110 \[104--115\] MSRV copies/pg of DNA) than in controls (Mean = 92 \[87--97\] MSRV copies/pg of DNA) (ANOVA; p = 4.15e-7) ([Figure 1A](#pone-0053623-g001){ref-type="fig"}). Beyond a strong significance of these data, since characterizing copy number variation in the genomic DNA of human cells from *ex vivo* samples, the presently improved method replicates results of previous studies [@pone.0053623-Perron1], [@pone.0053623-Mameli2]. In the original study showing an increase in MSRV DNA levels in MS patients (n = 8) compared to controls (n = 6) [@pone.0053623-Mameli2] authors measured the relative levels of MSRV DNA. It was found that MSRV *env* DNA load, but not that of Syncytin gene (*ERVWE1*), was increased in PBMCs of MS patients. In the present study this result is replicated in a higher number of patients (n = 178) and controls (n = 124). The present method includes normalization with a single-copy gene (*RNAse P*), verification of similar efficiencies for target and normalization gene assays and interplate calibration [@pone.0053623-Garson1]. Moreover, our data were systematically analyzed with a real-time PCR software (Genex®, MultiD analyses AB, Sweden). This method therefore avoids biases such as differences in DNA load or integrity, or resulting from interplate variability.

![MSRV DNA load MS diagnosis and sex.\
**A)** MSRV DNA load is more elevated in PBMC of MS patients (n = 178) than in controls (n = 124) (ANOVA; p = 4.15e-7). B**)** MSRV DNA load is more elevated in MS women (n = 112) than in control women (n = 70) (ANOVA; p = 0.009), control men (n = 54) (ANOVA; p = 8.87e-14) and MS men (n = 66) (ANOVA; p = 0.007). MSRV DNA load is more elevated in control women (n = 70) than in control men (n = 54) (ANOVA; p = 1.24e-6). Points represent the mean and bars represent 95% Confidence Interval of Mean. MSRV DNA load represents MSRV copies/pg of DNA.](pone.0053623.g001){#pone-0053623-g001}

The stratification by group and sex ([Figure 1B](#pone-0053623-g001){ref-type="fig"}) revealed that MSRV-*env* DNA load varies with the disease status of MS patients and with the gender. When considering differences between patients and controls, MS women (n = 112; Mean = 115 \[108--122\] MSRV copies/pg of DNA) had increased genomic load compared to control women (n = 70; Mean = 101 \[95--108\] MSRV copies/pg of DNA; ANOVA; p = 0.009). Similarly, MS men (n = 66; Mean = 101 \[94--108\] MSRV copies/pg of DNA) also had increased MSRV-*env* copies compared to control men (n = 54; Mean = 79 \[72--86\] MSRV copies/pg of DNA; ANOVA; p = 2.77e-6). When considering gender among MS patients, MSRV DNA copy number was elevated in women compared to men (ANOVA; p = 0.007) but, interestingly, among controls as well (ANOVA; p = 1.24e-6).

Elsewhere, determining the exact number of MSRV-type copies per genome is difficult both *in silico* and *ex-vivo*. Alignment of our primers and probe sequences on Ensembl database resulted in a potential detection of 39 copies spread in 17 chromosomes: 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 19, 20, 21 and X. However, this number can change according to the specificity of the BLAST. On the other hand, the number of MSRV-type copies can be different from one cell to another in MS patients, since expression of MSRV-env together with reverse transcriptase and retroviral particles is limited to a subpopulation of cells [@pone.0053623-Perron6]. In fact, as shown by Brudek et al. [@pone.0053623-Brudek1], only a percentage of monocytes and B-cells displayed an increased expression of HERV-W in active MS patients compared to controls. For these reasons, we have expressed our results in MSRV*-type* copies per pg of DNA, and not per cell.

The different loads of MSRV *env* DNA between men and women among control individuals could be related to the HERV-W *env* copies present in chromosome X (at least two per chromosome, as detected after alignment on Ensembl database), since they would be detected in duplicate in women.

The more elevated MSRV load in MS patients' DNA may then indicate that, in MS, the MSRV pathogenic copy can retrotranpose in PBMCs with active MSRV reverse-trancriptase [@pone.0053623-Perron7] and, eventually integrase [@pone.0053623-KomurianPradel1] through recombination/integration events. However, to determine if these new copies are actually retro-inserted, other complementary methods should be used as FISH or Southern Blotting, since reverse-transcribed copies may also remain episomal in cell nucleus.

Several groups have shown increased levels of MSRV-type or total HERV-W RNA transcription in serum, brain or PBMCs of MS patients compared to controls [@pone.0053623-Mameli1], [@pone.0053623-Nowak1], [@pone.0053623-deVilliers1]. The reverse-transcription and eventual retrotransposition of mRNA would favor an increase in its genomic copy number, thus detected among the whole PBMCs genomic DNA from present samples (comprising altogether Monocytes, NK cells, T- and B-Lymphocytes). Moreover, retrotransposition can lead to the formation of retrogenes which can be transcribed and translated [@pone.0053623-Feschotte1]. If such retrotransposed HERV-W*/*MSRV *env* copies were constitutively expressed, it would obviously aggravate the disease course. Indeed, regarding clinical evolution, EDSS ([Figure 2A](#pone-0053623-g002){ref-type="fig"}) and MSSS ([Figure 2B](#pone-0053623-g002){ref-type="fig"}) scores in women were higher among patients with a MSRV load above the Cut-Off of normal population (Cut-Off = 2.22, corresponding to 165 copies/pg of DNA; EDSS = 4.92 \[2.68--7.16\]; Mean MSSS = 6.40 \[3.50--9.30\] than among patients with a load below this normal threshold (Mean EDSS = 2.83 \[2.35--3.32\]; Mean MSSS = 3.92 \[3.29--4.54\]; ANOVA; p = 0.032 and p = 0.044, respectively).

![MSRV load and clinical evolution in women with MS.\
**A)** The EDSS Score is higher among patients with a MSRV DNA load above the Cut-Off\* (Cut-Off = 2.22, corresponding to 165 copies/pg of DNA) (n = 7) than below (n = 101). ANOVA; p = 0.032. **B)** MSSS score is higher among patients with a MSRV DNA load above the Cut-Off\*(n = 7) than below (n = 99). ANOVA; p = 0.044. Points represent the mean and bars represent 95% Confidence Interval of Mean. MSRV load represents MSRV copies/pg of DNA. \*Cut-Off = Mean ~log10~ ~MSRV\ DNA~ ~Controls~ +2\*S.D ~log10\ MSRV\ DNA~ ~Controls;~ This represents the threshold above which the values are no longer within the range of the normal population.](pone.0053623.g002){#pone-0053623-g002}

Although this result is interesting, the practical use of MSRV-type *env* DNA copy number as a biomarker for MS should be confirmed through longitudinal studies for comparison of DNA levels during different periods of the disease, as well as pre- and post-treatment.

Other groups have supported a potential usefulness of HERV-W*/*MSRV as MS biomarker. In longitudinal evaluations of MS patients during interferon-beta therapy MSRV RNA load in the blood was directly related to MS duration and it fell after 3 months of interferon-beta therapy [@pone.0053623-Mameli3]; besides, HERV-W protein detection by anti-envelope antibodies tended to decrease as a consequence of efficient IFN-beta therapy [@pone.0053623-Petersen1].

At this time there are no experimental proofs of *de novo* insertions of HERV-W. However, insertional polymorphism of another HERV family, the HERV-K, has been evidenced [@pone.0053623-Turner1], [@pone.0053623-Otowa1]. Moreover, a retroviral sequence highly similar to MSRV was identified by Representational Difference Analysis (RDA) in three pairs of monozygotic twins discordant for schizophrenia [@pone.0053623-DebRinker1] and the authors proposed that retroviral sequences transposing during fetal growth may alter neurodevelopmental genes and cause the disease.

The increased expression of HERV-W env and pol (that contains the highly conserved reverse transcriptase and integrase domains) in MS [@pone.0053623-KomurianPradel1] and the higher reverse-transcriptase activity found in MS patients [@pone.0053623-Brudek2] compared to controls strongly suggest that retro-integration of endogenous retroviral sequences could be an ongoing phenomenon occurring in some pathological conditions, leading to the increased levels of HERV DNA observed in MS. The reintegration of these sequences could also be mediated through long interspersed nuclear elements (LINEs), retroposons that have retained their ability to retrotranspose [@pone.0053623-Esnault1]. Indeed, it is has been shown that HERV-W processed pseudogenes have a strong preference for the insertion motif of long interspersed nuclear element (LINE) retrotransposons, suggesting that HERV-W processed pseudogenes arose by multiple and independent LINE-mediated retrotransposition of retroviral mRNA [@pone.0053623-Pavlicek1].

The more elevated MSRV*-type env* load in MS women would be compatible with the hypothesis of a genomic origin of MSRV in chromosome X harboring a complete MSRV provirus, most probably in a -yet unidentified- subgroup of individuals. This could possibly involve the ERVWE2 locus, though this locus is partially defective in the normal population, has nonetheless retained partial coding capacity and can produce an N-terminally truncated Env protein *in vitro* [@pone.0053623-Roebke1]. Alternatively, MSRV expression could result from the simultaneous presence of active proviral "mosaic" genes with orfs permitting a complete set to be expressed from such dispersed elements [@pone.0053623-KomurianPradel1], [@pone.0053623-Perron8].

This might be relevant, at least in some individuals, given the significant excess of retrogenes originating from the X chromosome in the human genome [@pone.0053623-Wang1], [@pone.0053623-Emerson1]. HERV-W molecular features, in conjunction with X chromosome ratio, could thus underlie the higher prevalence of the MS in women than in men (ratio 2--3∶1) [@pone.0053623-Greer1].

The higher prevalence of autoimmune diseases in women is a well known phenomenon. A putative localization of the genomic origin of MSRV in chromosome X would support the critical involvement of X chromosome gene products in the female predisposition to MS. In fact, sex-based differences in MS have been suggested to be due to defects in X chromosomes, including skewed X chromosome inactivation or reactivation of inactivated chromosome through loss of epigenetic control in women [@pone.0053623-Pennell1]. Reactivation of an inactivated X chromosome in women can thus result in an over-expression of certain X-linked genes affecting immune function [@pone.0053623-Lleo1].

These mechanisms have to be more deeply studied in order to clarify the source of such increase in MSRV-type copy number. On the other hand, other sources of variability as Microhomology-Mediated Break-Induced Replication that can lead to copy number variation cannot be ruled out [@pone.0053623-Hastings1].

From the present data available in the domain and our study results, it can be concluded that MSRV is likely to increase its DNA copy number in MS patients through reverse-transcription in PBMC and, possibly, with chromosomal retrotransposition. Its more elevated proviral load in women than in men could underlie gender differences in MS. Finally, the association with the clinical severity supports further investigations on the use of MSRV genomic load as a disease biomarker for MS.
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